The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery.

Fundamental & Clinical Pharmacology
Garima DuttaBin Liu

Abstract

Research in the last two decades has unveiled an important role for neuroinflammation in the degeneration of the nigrostriatal dopaminergic (DA) pathway that constitutes the pathological basis of the prevailing movement disorder, Parkinson's disease (PD). Neuroinflammation is characterized by the activation of brain glial cells, primarily microglia and astrocytes that release various soluble factors that include free radicals (reactive oxygen and nitrogen species), cytokines, and lipid metabolites. The majority of these glia-derived factors are proinflammatory and neurotoxic and are particularly deleterious to oxidative damage-vulnerable nigral DA neurons. As a proof of concept, various immunologic stimuli have been employed to directly induce glial activation to model DA neurodegeneration in PD. The bacterial endotoxin, lipopolysaccharide (LPS), has been the most extensively utilized glial activator for the induction of inflammatory DA neurodegeneration. In this review, we will summarize the various in vitro and in vivo LPS PD models. Furthermore, we will highlight the contribution of the LPS PD models to the mechanistic studies of PD pathogenesis and the search for neuroprotective agents for the treatment of PD.

References

Jan 1, 1979·Stroke; a Journal of Cerebral Circulation·D C Anderson, R E Cranford
Sep 1, 1992·Journal of Neurochemistry·M L Simmons, S Murphy
Apr 15, 1992·Cellular Immunology·J ZielasekH P Hartung
Sep 1, 1991·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·C R RaetzC F Nathan
Jan 1, 1988·Glia·W J StreitG W Kreutzberg
Jan 4, 1986·British Medical Journal·J W Norris, V C Hachinski
Oct 1, 1988·Journal of Neuroscience Research·E HetierA Prochiantz
Jun 1, 1993·Histopathology·P del Rio-Hortega
Jul 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·C C ChaoP K Peterson
Apr 1, 1997·Journal of Neurovirology·A OgataW W Hall
Jan 7, 1998·Trends in Neurosciences·J L RidetF H Gage
Jan 20, 1998·Developmental Medicine and Child Neurology·O Dammann, A Leviton
Jan 28, 1999·Neurology·J M GorellE L Peterson
Apr 15, 1999·Annual Review of Neuroscience·C W Olanow, W G Tatton
May 23, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·A E MedvedevS N Vogel
May 26, 2001·The Journal of Endocrinology·P DeleriveB Staels
Oct 6, 2001·Stroke; a Journal of Cerebral Circulation·E ArakiC Iadecola
Feb 9, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·ZaoDung LingPaul M Carvey
Apr 12, 2002·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Ranjita BetarbetJ Timothy Greenamyre
Jun 22, 2002·Annals of the New York Academy of Sciences·Bin LiuJau-Shyong Hong
Sep 3, 2002·Annals of Neurology·Miguel A HernánJuan J Gestal-Otero
Nov 14, 2002·Neurotoxicology·J William Langston
Dec 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Bin Liu, Jau-Shyong Hong

❮ Previous
Next ❯

Citations

Jul 24, 2012·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Wei BiEnxiang Tao
Mar 5, 2009·Cellular and Molecular Neurobiology·Julius BenickyJuan M Saavedra
Sep 22, 2009·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Anjana Yadav, Ronald G Collman
Aug 8, 2012·Neurotoxicity Research·Anna R Carta, Augusta Pisanu
Feb 21, 2013·ACS Chemical Neuroscience·J A Morales-GarcíaA Pérez-Castillo
Apr 23, 2013·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Marie-Francoise DoursoutRoger J Bick
Jan 2, 2013·Frontiers in Bioscience (Elite Edition)·Wei ZhangJau-Shyong Hong
Feb 19, 2011·Parkinson's Disease·Kemal Ugur TufekciKursad Genc
May 16, 2014·Translational Neurodegeneration·Francisco Pan-Montojo, Heinz Reichmann
Nov 30, 2013·Neural Plasticity·Jason R Richardson, Muhammad M Hossain
Feb 18, 2014·Journal of Neuroimmunology·Teresa TrottaMaria Antonietta Panaro
Jun 7, 2014·Brain Research Bulletin·Burak YulugWolf Rüdiger Schabitz
Aug 11, 2011·The International Journal of Neuroscience·Sarika SinghChandishwar Nath
Jun 23, 2009·Expert Opinion on Drug Safety·Bernardino OssolaPekka T Männistö
Sep 17, 2014·Journal of Neuroinflammation·Massimo LazzaroMassimo Alessio
Feb 5, 2013·Neurochemistry International·Randall L DavisCraig W Stevens
Jan 10, 2016·Neurotoxicity Research·Flávia V Santa-CecíliaRita Raisman-Vozari
Dec 15, 2015·BMC Medicine·Amos D Korczyn, Sharon Hassin-Baer
Jun 20, 2012·The European Journal of Neuroscience·Hanna S Lindgren, Stephen B Dunnett
Jul 21, 2015·Cellular and Molecular Neurobiology·Arpita SharmaIshan K Patro
Apr 9, 2015·Frontiers in Medicine·Pablo Granados-DuránPedro Fernández-Llebrez
Apr 25, 2016·Progress in Neurobiology·Valerie JoersAnna R Carta
Dec 7, 2013·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Fabíola Mara RibeiroAntonio Lucio Teixeira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Astrocytes in Parkinson Disease

Parkinson's disease (PD) is a neurodegenerative disorder caused by the progressive loss of dopaminergic neurons. Some PD-genes may be associated with astrocyte dysfunction. Discover the latest research on astrocytes in Parkinson's disease here.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Astrocytes & Neurodegeneration

Astrocytes are important for the health and function of the central nervous system. When these cells stop functioning properly, either through gain of function or loss of homeostatic controls, neurodegenerative diseases can occur. Here is the latest research on astrocytes and neurodegeneration.